COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,250 Articles (22,733 medRxiv, 8,517 bioRxiv)

Most recent first Previous |  Page 1423: Articles 14221-14230  | Next

Enhanced FcγRIII/CD16 activation by discrete ligands as independent correlates of disease severity in COVID-19 patients
Ankerhold, J., Giese, S., Kolb, P., Maul-Pavicic, A., Goeppert, N., Ciminski, K., Kreutz, C., Lother, A., Salzer, U., Bildl, W., Welsink, T., Morgenthaler, N., Busse Grawitz, A., Huzly, D., Schwemmle, M., Hengel, H., Falcone, V.
10.1101/2021.06.25.449893 — Posted: 2021-06-25
Use of hiPSC-derived cardiomyocytes to rule out proarrhythmic effects of drugs: the case of hydroxychloroquine in COVID-19
Sala, L., Leonov, V., Mura, M., Moretti, A., Crotti, L., Gnecchi, M., Schwartz, P. J.
10.1101/2021.06.25.449913 — Posted: 2021-06-25
Drug repurposing based on a Quantum-Inspired method versus classical fingerprinting uncovers potential antivirals against SARS-CoV-2 including vitamin B12
Jimenez-Guardeno, J. M., Ortega-Prieto, A. M., Menendez Moreno, B., Maguire, T. J. A., Diaz Hernandez, J. I., Diez Perez, J., Zuckerman, M., Mercadal Playa, A., Cordero Deline, C., Malim, M. H., Martinez-Nunez, R. T.
10.1101/2021.06.25.449609 — Posted: 2021-06-25
Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) Up to 15 Months Post-Infection
Patterson, B., Francisco, E. B., Yogendra, R., Long, E., Pise, A., Rodrigues, H., Hall, E., Herrera, o., Parikh, P., Guevara-Coto, J., Chang, X., Sacha, J. B., Rodriguez, R., Mora, J.
10.1101/2021.06.25.449905 — Posted: 2021-06-25 Discussion: Onsite
COVID-19 pandemic dynamics in India and impact of the SARS-CoV-2 Delta (B.1.617.2) variant
Yang, W., Shaman, J.
10.1101/2021.06.21.21259268 — Posted: 2021-06-25
Clinical profile and immediate outcome of Multisystem Inflammatory Syndrome in Children (MIS-C) associated with Covid-19: a multicentric study
Sethy, G., Mishra, B., Jain, M. K., Patnaik, S., Mishra, R., Behera, J. R., Sahoo, B.
10.1101/2021.06.21.21259259 — Posted: 2021-06-25
SARS-CoV-2 Breakthrough Infections in Fully Vaccinated Individuals
Ramirez, E., Wilkes, R. P., Carpi, G., Dorman, J., Bowen, C., Smith, L.
10.1101/2021.06.21.21258990 — Posted: 2021-06-25
Digital contact tracing contributes little to COVID-19 outbreak containment
Burdinski, A., Brockmann, D., Maier, B. F.
10.1101/2021.06.21.21259258 — Posted: 2021-06-25
SARS-CoV-2 Variants are Selecting for Spike Protein Mutations that Increase Protein Stability
Shorthouse, D., Hall, B. A.
10.1101/2021.06.25.449882 — Posted: 2021-06-25 Discussion: Offsite
Engineered chimeric T cell receptor fusion construct (TRuC)-expressing T cells prevent translational shutdown in SARS-CoV-2-infected cells
Godbole, I., Ciminski, K., Yousefi, O. S., Pathan-Chhatbar, S., Saltukoglu, D., Vesper, N., Salavei, P., Strietz, J., Gensch, N., Reth, M., Schwemmle, M., Schamel, W. W.
10.1101/2021.06.25.449871 — Posted: 2021-06-25

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).